leadf
logo-loader
viewAnteris Technologies Ltd

Admedus awaits Herpes Simplex Virus phase 2 clinical study results

au_admedus_lab_1_358_56c0fb04c18db.jpg

Admedus (ASX:AHZ) could have the highly anticipated interim results available for its Phase 2 clinical study for a Herpes Simplex Virus (HSV-2) therapeutic vaccine in the coming weeks.

HSV-2 is the major causative agent of genital herpes and further positive trial results would provide a boost to infected individuals and to the commercialisation potential of the vaccine.

The economic burden of genital HSV infection and resulting complications is estimated to be greater than $1 billion annually in the U.S. alone.

Further HSV-2 study data is expected to be released during 2016.

The HSV-2 Phase II study had 40 study participants and each study participant will receive either the vaccine or a placebo. The vaccine is initially given as a 3 injection vaccination program, four weeks apart, plus study participants will also receive another injection, a ‘booster’ as it were, 6 months after the last of the 3 vaccinations.

The study is designed to examine the safety of the HSV-2 vaccine in people with HSV-2 as well as look at its ability to stimulate an immune response against the virus.

The Company and the clinical study investigators remain blinded to the study data in accordance with standard clinical study procedures to protect the integrity of the results.

Inventor Professor Ian Frazer's company developed the next generation technology and is now majority controlled by Admedus.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Quick facts: Anteris Technologies Ltd

Price: 4 AUD

ASX:AVR
Market: ASX
Market Cap: $23.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read